Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free AURA Stock Alerts

Aura Biosciences (AURA) Financials

Aura Biosciences logo
$7.56 +0.19 (+2.58%)
As of 09/4/2026 04:00 PM Eastern
Compare
Annual Income Statements for Aura Biosciences

Annual Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -22 -35 -59 -76 -87 -106
Consolidated Net Income / (Loss)		 -22 -35 -59 -76 -87 -106
Net Income / (Loss) Continuing Operations		 -22 -35 -59 -76 -87 -106
Total Pre-Tax Income 		-22 -35 -59 -76 -87 -106
Total Operating Income		 -22 -35 -60 -85 -96 -113
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 22 35 60 85 96 113
Selling, General & Admin Expense		 4.16 10 18 20 23 22
Research & Development Expense		 18 25 42 65 73 90
Total Other Income / (Expense), net		 0.00 0.01 1.53 8.72 9.31 6.71
Interest Expense		 0.00 -0.01 -1.86 -8.59 -9.43 -6.63
Other Income / (Expense), net		 0.00 -0.00 -0.33 0.13 -0.12 0.08
Income Tax Expense		 - - 0.00 0.14 0.11 0.11
Basic Earnings per Share		 ($82.06) ($8.95) ($1.96) ($1.93) ($1.75) ($1.76)
Weighted Average Basic Shares Outstanding		 367.20K 5.16M 29.94M 39.62M 49.65M 60.34M
Diluted Earnings per Share		 ($82.06) ($8.95) ($1.96) ($1.93) ($1.75) ($1.76)
Weighted Average Diluted Shares Outstanding		 367.20K 5.16M 29.94M 39.62M 49.65M 60.34M
Weighted Average Basic & Diluted Shares Outstanding		 367.20K 5.16M 37.80M 49.50M 50.23M 64.15M

Quarterly Income Statements for Aura Biosciences

This table shows Aura Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34 -46
Consolidated Net Income / (Loss)		 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34 -46
Net Income / (Loss) Continuing Operations		 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34 -46
Total Pre-Tax Income 		-22 -20 -20 -21 -26 -27 -27 -26 -26 -34 -46
Total Operating Income		 -25 -22 -23 -23 -28 -29 -29 -28 -27 -35 -48
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 25 22 23 23 28 29 29 28 27 35 48
Selling, General & Admin Expense		 4.50 5.26 5.88 6.20 5.47 5.69 5.73 5.73 5.34 6.91 17
Research & Development Expense		 20 17 17 17 22 23 23 22 22 28 31
Total Other Income / (Expense), net		 2.79 2.65 2.43 2.23 2.00 1.57 1.64 1.80 1.69 1.19 2.46
Interest Expense		 -2.61 -2.69 -2.45 -2.26 -2.04 -1.59 -1.68 -1.82 -1.54 -1.19 -2.31
Other Income / (Expense), net		 0.18 -0.03 -0.03 -0.03 -0.04 -0.02 -0.04 -0.01 0.15 0.00 0.15
Income Tax Expense		 0.14 0.05 0.00 0.04 0.02 0.02 0.05 0.03 0.02 0.01 0.03
Basic Earnings per Share		 ($0.51) ($0.40) ($0.41) ($0.42) ($0.52) ($0.55) ($0.47) ($0.40) ($0.34) ($0.50) ($0.48)
Weighted Average Basic Shares Outstanding		 39.62M 49.45M 49.55M 49.66M 49.65M 50.13M 58.02M 65.94M 60.34M 67.45M 94.86M
Diluted Earnings per Share		 ($0.51) ($0.40) ($0.41) ($0.42) ($0.52) ($0.55) ($0.47) ($0.40) ($0.34) ($0.50) ($0.48)
Weighted Average Diluted Shares Outstanding		 39.62M 49.45M 49.55M 49.66M 49.65M 50.13M 58.02M 65.94M 60.34M 67.45M 94.86M
Weighted Average Basic & Diluted Shares Outstanding		 49.50M 49.54M 49.61M 49.95M 50.23M 50.27M 62.12M 63.50M 64.15M 103.39M 103.70M

Annual Cash Flow Statements for Aura Biosciences

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -15 132 -27 -81 -9.39 28
Net Cash From Operating Activities		 -24 -32 -55 -64 -80 -85
Net Cash From Continuing Operating Activities		 -24 -32 -55 -64 -80 -85
Net Income / (Loss) Continuing Operations		 -22 -35 -59 -76 -87 -106
Consolidated Net Income / (Loss)		 -22 -35 -59 -76 -87 -106
Depreciation Expense		 0.83 0.83 1.18 1.30 1.22 1.13
Non-Cash Adjustments To Reconcile Net Income		 0.73 2.31 6.09 6.83 8.53 14
Changes in Operating Assets and Liabilities, net		 -3.68 -0.30 -3.10 4.44 -2.64 5.97
Net Cash From Investing Activities		 -0.77 -2.13 -68 -114 69 36
Net Cash From Continuing Investing Activities		 -0.77 -2.13 -68 -114 69 36
Purchase of Property, Plant & Equipment		 -0.77 -2.13 -1.09 -0.71 -1.25 -0.45
Purchase of Investments		 - 0.00 -120 -234 -59 -84
Sale and/or Maturity of Investments		 - 0.00 53 120 129 120
Net Cash From Financing Activities		 10 166 96 97 1.60 77
Net Cash From Continuing Financing Activities		 10 166 96 97 1.60 77
Issuance of Common Equity		 0.00 79 95 96 0.18 76
Other Financing Activities, net		 0.16 0.35 0.43 1.38 1.42 1.01
Effect of Exchange Rate Changes		 - - - - 0.00 -0.19

Quarterly Cash Flow Statements for Aura Biosciences

This table details how cash moves in and out of Aura Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -15 -15 3.80 -4.67 6.29 6.55 69 -60 12 25 -17
Net Cash From Operating Activities		 -17 -24 -16 -15 -24 -23 -21 -20 -20 -30 -33
Net Cash From Continuing Operating Activities		 -17 -24 -16 -15 -24 -23 -21 -20 -20 -30 -32
Net Income / (Loss) Continuing Operations		 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34 -46
Consolidated Net Income / (Loss)		 -22 -20 -20 -21 -26 -27 -27 -26 -26 -34 -46
Depreciation Expense		 0.32 0.31 0.31 0.31 0.29 0.29 0.29 0.28 0.27 0.27 0.26
Non-Cash Adjustments To Reconcile Net Income		 2.39 1.52 2.41 2.08 2.53 3.41 3.30 4.33 3.33 3.94 13
Changes in Operating Assets and Liabilities, net		 2.03 -6.57 1.49 3.38 -0.94 0.42 2.66 1.31 1.56 -0.43 0.41
Net Cash From Investing Activities		 -90 9.40 20 9.89 30 30 20 -44 30 55 -226
Net Cash From Continuing Investing Activities		 -90 9.27 20 9.89 30 30 20 -44 30 55 -226
Purchase of Property, Plant & Equipment		 -0.32 -0.21 -0.40 -0.34 -0.30 -0.19 -0.04 -0.05 -0.18 -0.10 -0.02
Purchase of Investments		 -145 -29 -9.90 -20 - 0.00 -9.98 -74 - 0.00 -256
Sale and/or Maturity of Investments		 55 39 30 30 30 30 30 30 30 55 30
Net Cash From Financing Activities		 93 0.25 0.08 0.72 0.54 0.10 70 4.36 2.77 0.30 242
Net Cash From Continuing Financing Activities		 93 0.25 0.08 0.72 0.54 0.10 70 4.36 2.77 0.30 242
Issuance of Common Equity		 93 0.10 - 0.08 - 0.10 70 3.36 2.77 0.12 281
Other Financing Activities, net		 0.37 0.16 0.08 0.63 0.54 0.00 0.00 1.01 - 0.18 0.08
Effect of Exchange Rate Changes		 - - - - - -0.02 - - -0.16 -0.03 -0.17

Annual Balance Sheets for Aura Biosciences

This table presents Aura Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 22 160 224 255 183 169
Total Current Assets		 18 154 197 232 161 150
Cash & Equivalents		 17 149 122 41 32 60
Short-Term Investments		 - 0.00 67 185 119 85
Prepaid Expenses		 1.04 4.62 7.87 5.63 9.53 5.50
Plant, Property, & Equipment, net		 3.57 5.25 5.37 3.15 3.22 2.62
Total Noncurrent Assets		 0.08 1.08 22 20 19 17
Other Noncurrent Operating Assets		 0.00 0.95 21 19 18 16
Other Noncurrent Nonoperating Assets		 0.08 0.13 0.77 0.77 0.77 0.77
Total Liabilities & Shareholders' Equity		 22 160 224 255 183 169
Total Liabilities		 2.74 7.72 28 29 31 33
Total Current Liabilities		 2.66 7.36 10 12 15 18
Accounts Payable		 0.61 2.40 2.92 1.79 2.30 1.55
Accrued Expenses		 2.05 4.34 4.57 7.88 9.46 14
Other Current Liabilities		 0.00 0.62 2.96 2.69 3.15 3.24
Total Noncurrent Liabilities		 0.08 0.36 18 17 16 14
Other Noncurrent Operating Liabilities		 0.07 0.36 18 17 16 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -109 152 196 226 152 137
Total Preferred & Common Equity		 -109 152 196 226 152 137
Total Common Equity		 -109 152 196 226 152 137
Common Stock		 8.17 304 407 513 526 617
Retained Earnings		 -117 -152 -211 -287 -374 -480
Treasury Stock		 - - - - - 0.00
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.07 0.54 0.26 -0.10

Quarterly Balance Sheets for Aura Biosciences

This table presents Aura Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 206 193 180 235 218 205 155 204 190 138 348
Total Current Assets		 179 166 154 212 196 183 135 184 170 119 329
Cash & Equivalents		 38 48 56 26 30 25 38 107 48 85 68
Short-Term Investments		 135 114 93 177 157 149 90 70 114 30 256
Prepaid Expenses		 5.58 4.18 4.81 9.38 8.18 9.10 6.53 6.65 8.25 3.77 5.19
Plant, Property, & Equipment, net		 5.17 5.06 4.86 3.05 3.33 3.33 3.11 2.86 2.63 2.47 2.20
Total Noncurrent Assets		 22 21 21 20 19 19 18 18 17 17 17
Other Noncurrent Operating Assets		 21 21 20 19 19 18 17 17 17 16 16
Other Noncurrent Nonoperating Assets		 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.77
Total Liabilities & Shareholders' Equity		 206 193 180 235 218 205 155 204 190 138 348
Total Liabilities		 26 26 28 26 27 31 27 30 33 30 33
Total Current Liabilities		 8.11 8.90 11 9.66 11 15 12 15 19 17 20
Accounts Payable		 1.06 0.55 1.49 1.93 1.46 1.99 2.01 1.29 1.89 2.57 2.25
Accrued Expenses		 4.07 5.33 6.37 4.99 6.34 9.60 6.99 10 14 11 14
Other Current Liabilities		 2.99 3.01 3.04 2.74 2.75 3.13 3.17 3.20 3.22 3.27 3.29
Total Noncurrent Liabilities		 18 17 17 17 16 16 15 15 15 14 13
Other Noncurrent Operating Liabilities		 18 17 17 17 16 16 15 15 15 14 13
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 180 166 152 209 191 175 128 175 157 107 315
Total Preferred & Common Equity		 180 166 152 209 191 175 128 175 157 107 315
Total Common Equity		 180 166 152 209 191 175 128 175 157 107 315
Common Stock		 409 413 417 516 519 522 530 603 611 622 915
Retained Earnings		 -228 -247 -265 -307 -327 -348 -402 -429 -455 -514 -560
Accumulated Other Comprehensive Income / (Loss)		 -0.05 -0.22 -0.13 0.02 -0.18 0.61 0.11 0.03 0.07 -0.21 -0.67
Other Equity Adjustments		 - - - - - - - - - - -39

Annual Metrics And Ratios for Aura Biosciences

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 29,210,549.00 - - - 63,503,269.00
DEI Adjusted Shares Outstanding		 0.00 29,210,549.00 - - - 63,503,269.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.21 - - - -1.67
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -61.06% -72.71% -40.56% -13.70% -17.44%
EBIT Growth		 0.00% -58.78% -71.98% -39.97% -13.41% -17.12%
NOPAT Growth		 0.00% -58.74% -71.05% -40.96% -13.09% -17.35%
Net Income Growth		 0.00% -58.75% -66.70% -30.03% -13.76% -22.17%
EPS Growth		 0.00% 89.09% 78.10% 1.53% 9.33% -0.57%
Operating Cash Flow Growth		 0.00% -33.26% -68.47% -16.93% -24.99% -6.19%
Free Cash Flow Firm Growth		 0.00% 0.00% -74.06% -16.27% -30.63% -3.32%
Invested Capital Growth		 0.00% 65.46% 92.78% -118.20% 109.92% -7,596.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -24.84% -9.11% -3.57% 0.66%
EBIT Q/Q Growth		 0.00% 0.00% -24.48% -8.96% -3.49% 0.67%
NOPAT Q/Q Growth		 0.00% 0.00% -24.63% -9.21% -3.25% 0.50%
Net Income Q/Q Growth		 0.00% 0.00% -9.15% -7.87% -4.45% 0.26%
EPS Q/Q Growth		 0.00% 0.00% -102.92% 0.52% -0.57% 9.28%
Operating Cash Flow Q/Q Growth		 0.00% -34.59% -12.18% 0.97% -8.96% 3.95%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 2.50% -9.02% 4.22%
Invested Capital Q/Q Growth		 0.00% 0.00% 131.49% -158.11% 122.64% -35.68%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.03% 100.00% 100.18% 100.13% 100.10%
Interest Burden Percent		 100.01% 99.96% 96.93% 89.88% 90.20% 94.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -114.68% -41.07% -33.78% -36.26% -46.01% -73.52%
Cash Return on Invested Capital (CROIC)		 0.00% -1,040.28% -992.22% 0.00% -63,405.74% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 643.88% -10.43% -33.78% -36.26% -46.01% -73.52%
Return on Equity Simple (ROE_SIMPLE)		 20.43% -23.14% -30.05% -33.83% -57.19% 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -25 -42 -59 -67 -79
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -38.10% -12.69% -9.77% -8.12% -10.37% -18.35%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -26.34% -44.27% -57.67%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -35 -61 -85 -96 -113
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -34 -59 -84 -95 -112
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 3.26 1.57 1.50 2.70 2.53
Price to Tangible Book Value (P/TBV)		 0.00 3.26 1.57 1.50 2.70 2.53
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 99.29 111.76 19.92 0.00 2,402.84 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.97 -0.97 -0.99 -1.00 -1.03
Leverage Ratio		 1.14 1.06 1.10 1.14 1.16 1.22
Compound Leverage Factor		 1.14 1.06 1.07 1.02 1.04 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 661.45% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -561.45% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.69 37.61 5.30 5.32 4.42 1.15
Noncontrolling Interest Sharing Ratio		 661.45% 74.60% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 6.94 20.90 18.81 18.76 10.77 8.15
Quick Ratio		 6.54 20.27 18.06 18.30 10.13 7.85
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -26 -45 -52 -68 -71
Operating Cash Flow to CapEx		 -3,154.47% -1,525.18% -4,990.95% -9,005.22% -6,369.11% -18,957.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -8,107.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -8,364.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 1.88 3.10 5.98 -1.09 0.11 -8.10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.23 2.88 -7.07 1.20 -8.20
Enterprise Value (EV)		 186 347 119 113 260 202
Market Capitalization		 76 496 308 339 411 346
Book Value per Share		 ($296.06) $5.21 $6.67 $5.90 $3.04 $2.16
Tangible Book Value per Share		 ($296.06) $5.21 $6.67 $5.90 $3.04 $2.16
Total Capital		 19 152 196 226 152 137
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -17 -149 -189 -226 -151 -144
Capital Expenditures (CapEx)		 0.77 2.13 1.09 0.71 1.25 0.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.62 -2.74 -2.59 -6.73 -5.38 -13
Debt-free Net Working Capital (DFNWC)		 16 146 186 219 146 131
Net Working Capital (NWC)		 16 146 186 219 146 131
Net Nonoperating Expense (NNE)		 6.66 11 17 17 20 27
Net Nonoperating Obligations (NNO)		 -17 -149 -190 -227 -152 -145
Total Depreciation and Amortization (D&A)		 0.83 0.83 1.18 1.30 1.22 1.13
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($8.95) ($1.96) ($1.93) ($1.75) ($1.76)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 29.22M 29.94M 39.62M 49.65M 60.34M
Adjusted Diluted Earnings per Share		 $0.00 ($8.95) ($1.96) ($1.93) ($1.75) ($1.76)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 29.22M 29.94M 39.62M 49.65M 60.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($8.95) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 5.16M 37.80M 49.50M 50.23M 64.15M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -25 -42 -59 -67 -79
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -7,401.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -5,181.40 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -7,658.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -5,438.40 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Aura Biosciences

This table displays calculated financial ratios and metrics derived from Aura Biosciences' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 50,225,312.00 50,268,758.00 62,119,873.00 63,503,269.00 64,150,468.00 103,386,558.00
DEI Adjusted Shares Outstanding		 - - - - - 50,225,312.00 50,268,758.00 62,119,873.00 63,503,269.00 64,150,468.00 103,386,558.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -0.55 -0.54 -0.42 -0.40 -0.53 -0.44
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -40.33% -15.21% -12.33% -13.87% -13.50% -30.53% -26.20% -20.46% 2.69% -20.24% -68.02%
EBIT Growth		 -39.60% -14.84% -12.21% -13.49% -13.19% -30.05% -25.72% -20.05% 2.73% -19.98% -67.25%
NOPAT Growth		 -40.71% -14.76% -12.26% -13.39% -12.21% -30.13% -25.71% -20.12% 2.06% -20.08% -68.00%
Net Income Growth		 -33.65% -12.82% -11.14% -13.67% -16.73% -39.47% -32.86% -24.18% 1.06% -22.57% -68.91%
EPS Growth		 1.92% 13.04% 14.58% 12.50% -1.96% -37.50% -14.63% 4.76% 34.62% 9.09% -2.13%
Operating Cash Flow Growth		 3.48% -48.99% -10.13% 0.84% -37.76% 4.49% -28.81% -31.89% 14.54% -27.99% -56.45%
Free Cash Flow Firm Growth		 32.44% -24.45% -32.04% -2.06% -101.10% 2.85% 14.51% -0.95% 47.43% -17.75% -108.56%
Invested Capital Growth		 -118.20% -13.57% -10.07% -125.45% 109.92% -115.43% -205.50% -1,150.94% -7,596.30% -940.86% -170.75%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -20.48% 9.22% -1.98% -2.09% -20.10% -4.40% 1.41% 2.55% 2.98% -29.00% -37.77%
EBIT Q/Q Growth		 -20.05% 9.17% -1.98% -2.06% -19.73% -4.36% 1.41% 2.55% 2.98% -28.71% -37.43%
NOPAT Q/Q Growth		 -20.96% 9.97% -2.01% -2.06% -19.70% -4.41% 1.45% 2.47% 2.40% -28.01% -37.87%
Net Income Q/Q Growth		 -19.55% 10.96% -3.20% -3.47% -22.77% -6.38% 1.69% 3.29% 2.19% -31.79% -35.48%
EPS Q/Q Growth		 -6.25% 21.57% -2.50% -2.44% -23.81% -5.77% 14.55% 14.89% 15.00% -47.06% 4.00%
Operating Cash Flow Q/Q Growth		 -12.88% -40.63% 34.04% 5.30% -56.83% 2.49% 11.05% 3.03% -1.61% -46.04% -8.72%
Free Cash Flow Firm Q/Q Growth		 24.62% -44.16% -5.10% 10.64% -48.54% 30.36% 7.51% -5.52% 22.66% -56.01% -63.81%
Invested Capital Q/Q Growth		 -158.11% 572.08% -36.39% -114.59% 122.64% -834.26% -335.06% -72.96% -35.68% -1.95% -13.17%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.62% 100.23% 100.00% 100.20% 100.09% 100.07% 100.18% 100.10% 100.06% 100.03% 100.06%
Interest Burden Percent		 89.40% 87.98% 89.24% 90.29% 92.69% 94.51% 94.14% 93.50% 94.30% 96.59% 95.19%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -36.26% -40.43% -45.09% -50.99% -46.01% -56.24% -55.39% -64.26% -73.52% -95.57% -53.49%
Cash Return on Invested Capital (CROIC)		 0.00% -1,094.69% -1,820.92% 0.00% -63,405.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -36.26% -40.43% -45.09% -50.99% -46.01% -56.24% -55.39% -64.26% -73.52% -95.57% -53.49%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -37.67% -42.14% -47.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -17 -16 -16 -16 -19 -20 -20 -20 -19 -24 -34
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.30% -2.16% -2.51% -2.94% -3.36% -4.31% -3.82% -3.91% -4.37% -7.60% -4.77%
Return On Investment Capital (ROIC_SIMPLE)		 -7.68% - - - -12.81% -15.88% -11.47% -12.47% -13.93% -22.76% -10.67%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -25 -22 -23 -23 -28 -29 -29 -28 -27 -35 -48
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -22 -22 -23 -28 -29 -28 -28 -27 -35 -48
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.50 1.86 1.96 2.53 2.70 2.30 1.80 2.45 2.53 4.00 2.33
Price to Tangible Book Value (P/TBV)		 1.50 1.86 1.96 2.53 2.70 2.30 1.80 2.45 2.53 4.00 2.33
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 36.13 57.23 0.00 2,402.84 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.99 -0.97 -0.98 -1.00 -1.00 -0.99 -1.00 -1.02 -1.03 -1.04 -1.03
Leverage Ratio		 1.14 1.13 1.15 1.18 1.16 1.16 1.15 1.19 1.22 1.25 1.13
Compound Leverage Factor		 1.02 1.00 1.02 1.07 1.07 1.10 1.09 1.12 1.15 1.20 1.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.10 7.78 6.95 6.88 5.65 3.15 3.94 4.02 2.82 3.29 11.76
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.76 21.97 18.54 12.47 10.77 11.06 12.39 9.04 8.15 7.09 16.82
Quick Ratio		 18.30 20.99 17.77 11.85 10.13 10.52 11.94 8.60 7.85 6.87 16.56
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -10 -15 -16 -14 -21 -14 -13 -14 -11 -17 -28
Operating Cash Flow to CapEx		 -5,484.86% -11,643.81% -4,001.99% -4,478.89% -8,010.70% -12,489.30% -53,266.67% -44,764.44% -11,630.11% -29,306.86% -154,766.67%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.09 5.14 3.27 -0.48 0.11 -0.79 -3.45 -5.97 -8.10 -8.25 -9.34
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -7.07 -0.81 -0.37 -2.35 1.20 -5.93 -6.72 -5.49 -8.20 -7.46 -5.89
Enterprise Value (EV)		 113 186 187 268 260 166 137 222 202 314 410
Market Capitalization		 339 389 375 442 411 294 315 384 346 429 734
Book Value per Share		 $5.90 $4.22 $3.86 $3.52 $3.04 $2.55 $3.47 $2.52 $2.16 $1.67 $3.05
Tangible Book Value per Share		 $5.90 $4.22 $3.86 $3.52 $3.04 $2.55 $3.47 $2.52 $2.16 $1.67 $3.05
Total Capital		 226 209 191 175 152 128 175 157 137 107 315
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -226 -203 -187 -174 -151 -128 -177 -162 -144 -115 -324
Capital Expenditures (CapEx)		 0.32 0.21 0.40 0.34 0.30 0.19 0.04 0.05 0.18 0.10 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.73 -0.29 -2.37 -5.61 -5.38 -5.64 -8.21 -11 -13 -13 -14
Debt-free Net Working Capital (DFNWC)		 219 203 185 169 146 122 169 151 131 102 309
Net Working Capital (NWC)		 219 203 185 169 146 122 169 151 131 102 309
Net Nonoperating Expense (NNE)		 4.78 4.09 4.40 4.78 6.37 7.16 6.99 6.60 6.49 9.28 12
Net Nonoperating Obligations (NNO)		 -227 -204 -188 -175 -152 -129 -178 -163 -145 -116 -325
Total Depreciation and Amortization (D&A)		 0.32 0.31 0.31 0.31 0.29 0.29 0.29 0.28 0.27 0.27 0.26
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.51) ($0.40) ($0.41) ($0.42) ($0.52) ($0.55) ($0.47) ($0.40) ($0.34) ($0.50) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding		 39.62M 49.45M 49.55M 49.66M 49.65M 50.13M 58.02M 65.94M 60.34M 67.45M 94.86M
Adjusted Diluted Earnings per Share		 ($0.51) ($0.40) ($0.41) ($0.42) ($0.52) ($0.55) ($0.47) ($0.40) ($0.34) ($0.50) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding		 39.62M 49.45M 49.55M 49.66M 49.65M 50.13M 58.02M 65.94M 60.34M 67.45M 94.86M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.50M 49.54M 49.61M 49.95M 50.23M 50.27M 62.12M 63.50M 64.15M 103.39M 103.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -17 -16 -16 -16 -19 -20 -20 -20 -19 -24 -34
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Aura Biosciences remains a development-stage biotechnology company with no reported revenue. Revenue has been zero in every quarter provided, so financial performance continues to depend on research progress, clinical milestones and the company’s ability to raise capital rather than product sales.

Operating losses have widened. Quarterly operating expenses increased from approximately $20.3 million in Q2 2023 and $22.3 million in Q1 2024 to $48.1 million in Q2 2026. Research and development spending was $30.7 million in Q2 2026, up from $28.0 million in Q1 and $22.9 million in Q2 2025. The company reported a $45.6 million net loss, or $0.48 per share, in Q2 2026, compared with a $33.7 million loss in Q1 2026 and a $27.0 million loss in Q2 2025.

Cash burn remains substantial. Aura used $32.5 million in operating cash during Q2 2026, compared with $29.9 million in Q1 2026 and $20.8 million in Q2 2025. Operating cash flow has been negative in every quarter presented, underscoring the company’s continued dependence on external financing.

The balance sheet was significantly strengthened by financing activity during the latest quarter. At June 30, 2026, Aura held $67.8 million in cash and $256.0 million in short-term investments, or approximately $323.8 million in combined cash and investments. However, the company raised $280.8 million through common equity issuance in Q2, while investing $256.0 million in short-term investments. As a result, the quarter’s $17.0 million decline in cash and equivalents largely reflects the transfer of funds into investments rather than a comparable reduction in overall liquidity.

  • Liquidity improved materially: Cash and short-term investments totaled approximately $323.8 million at the end of Q2 2026, up from roughly $114.7 million at the end of Q1 2026.
  • Low balance-sheet leverage: Total liabilities were $32.9 million versus $348.1 million of assets, and current assets exceeded current liabilities by approximately 16.8 times.
  • Recent financing provides additional development capital: The $280.8 million common equity issuance substantially increased the company’s resources for clinical development and other operations.
  • Investment holdings can generate financial income: Short-term investments have remained a major component of Aura’s assets, helping provide interest-related income while capital is held before it is needed for operations.
  • Estimated liquidity runway is meaningful but uncertain: Using Q2 operating cash usage of $32.5 million as a simple reference, combined cash and investments could cover roughly 10 quarters of similar burn. This is not a forecast, particularly because spending is rising and clinical programs can require significant additional capital.
  • Capital is being redeployed into investments: The large Q2 investment purchase explains much of the decline in cash, but investors should monitor the liquidity, maturity and return characteristics of these holdings.
  • No revenue or gross profit has been reported: Aura has not yet demonstrated commercial sales, leaving its financial outlook dependent on pipeline execution and future financing.
  • Losses and research spending are accelerating: Q2 2026 operating expenses rose approximately 38% from Q2 2025, while the quarterly net loss increased by about 69%.
  • Operating cash flow remains consistently negative: The company has not reached cash-flow breakeven and used $32.5 million for operations in the latest quarter.
  • Shareholder dilution has increased: Weighted-average basic shares rose from approximately 49.5 million in Q1 2024 to 94.9 million in Q2 2026. The latest equity raise strengthened the balance sheet but reduced each existing shareholder’s proportional ownership.

Overall, Aura’s financial position is currently supported by a large equity-funded liquidity cushion and minimal liabilities. The main risks are the absence of revenue, rising clinical and administrative costs, persistent cash burn and continued reliance on equity financing. Investors should focus on whether future clinical progress can justify the higher spending and eventually support a transition from capital consumption to commercial revenue.

09/05/26 03:56 AM ETAI Generated. May Contain Errors.

Aura Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Aura Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Aura Biosciences' net income appears to be on an upward trend, with a most recent value of -$106.19 million in 2025, rising from -$22.21 million in 2020. The previous period was -$86.92 million in 2024. See Aura Biosciences' forecast for analyst expectations on what's next for the company.

Aura Biosciences' total operating income in 2025 was -$112.79 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $112.79 million

Over the last 5 years, Aura Biosciences' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Aura Biosciences' total liabilities were at $32.52 million at the end of 2025, a 6.5% increase from 2024, and a 1,086.3% increase since 2020.

In the past 5 years, Aura Biosciences' cash and equivalents has ranged from $17.39 million in 2020 to $149.06 million in 2021, and is currently $59.52 million as of their latest financial filing in 2025.

Over the last 5 years, Aura Biosciences' book value per share changed from -296.06 in 2020 to 2.16 in 2025, a change of -100.7%.


Related Companies

Financial statements for NASDAQ:AURA last updated on 8/11/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel